Cite
Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
MLA
Kensei Tobinai, et al. “Dose‐escalation Study of Tabalumab with Bortezomib and Dexamethasone in Japanese Patients with Multiple Myeloma.” Cancer Science, vol. 107, Sept. 2016, pp. 1281–89. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f7a88b4bdfa482529888010d8bb1968f&authtype=sso&custid=ns315887.
APA
Kensei Tobinai, Kazunori Uenaka, Tsuyoshi Ishiki, Soshi Nagaoka, Shinsuke Iida, Hiroya Asou, Kaijiro Maeda, Daisuke Ogiya, Masafumi Taniwaki, Yasunobu Abe, & Ilaria Conti. (2016). Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma. Cancer Science, 107, 1281–1289.
Chicago
Kensei Tobinai, Kazunori Uenaka, Tsuyoshi Ishiki, Soshi Nagaoka, Shinsuke Iida, Hiroya Asou, Kaijiro Maeda, et al. 2016. “Dose‐escalation Study of Tabalumab with Bortezomib and Dexamethasone in Japanese Patients with Multiple Myeloma.” Cancer Science 107 (September): 1281–89. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f7a88b4bdfa482529888010d8bb1968f&authtype=sso&custid=ns315887.